Výsledky vyhledávání - "Proudfoot, C"

Akademický článek

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

Autor: Fournier M, Chen C, Kuznik A, Proudfoot C, Mallya UG, Michaud K

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 117-128 (2019)

Marie Fournier,1 Chieh-I Chen,2 Andreas Kuznik,2 Clare Proudfoot,3 Usha G Mallya,4 Kaleb Michaud5,6 1Health Economics & Value Assessment, Sanofi France, Chilly-Mazarin, France; 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 3Sanofi, Guildford,

Externí odkaz: https://doaj.org/article/8cdf5874e3914c54949d917ae129aaa4

Zobrazit plný text záznamu

Akademický článek

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

Autor: Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen C

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 805-819 (2018)

Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US

Externí odkaz: https://doaj.org/article/2cb42a7ee40a4d17ae7d3126f41f459d

Zobrazit plný text záznamu

Akademický článek

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Autor: Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen C

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 83-85 (2019)

Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819. On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs

Externí odkaz: https://doaj.org/article/b61d1c10d3744f8ab178e730cc4f2551

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

WCN23-0369 SYMPTOM BURDEN OF PATIENTS WITH IgA NEPHROPATHY IN A REAL WORLD SETTING ACROSS GEOGRAPHIES

Autor: Lafayette, R., Smeets, S., Kattlun, J., George, A.T., Aldworth, C., Proudfoot, C., Wang, W., de Courcy, J., Yao, L., Roccatello, D.

Publikováno v: In Kidney International Reports March 2023 8(3) Supplement:S257-S258

Zobrazit plný text záznamu

Akademický článek

POSA345 Characterising Patient Preferences for Treatment Attributes in Heart Failure with Preserved Ejection Fraction

Autor: Johnson, SJ, Munro, B, Proudfoot, C

Publikováno v: In Value in Health January 2022 25(1) Supplement:S216-S216

Zobrazit plný text záznamu

Akademický článek

POSC142 Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Indian Healthcare Setting

Autor: Gokhale, S, Partha, G, Proudfoot, C, Anand, S

Publikováno v: In Value in Health January 2022 25(1) Supplement:S115-S115

Zobrazit plný text záznamu

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy

Autor: Bonafede, M. M. K., Mcmorrow, D., Proudfoot, C., Shinde, S., Andreas Kuznik, Chen, C. -I

Publikováno v: Scopus-Elsevier

Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d26b98d49285de18297b2a494b86f2c7
https://europepmc.org/articles/PMC6207310/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání